Literature DB >> 22302229

Call it cancer.

Bruce A Chabner, Matthew Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22302229      PMCID： PMC3286158          DOI： 10.1634/theoncologist.2012-0004

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

2.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

3.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

4.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Vish Viswanath; Hunter Wessells
Journal:  NIH Consens State Sci Statements       Date:  2011 Dec 5-7
  5 in total
  5 in total

1.  Call it cancer: letting the histopathology determine the diagnosis.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2012-04-17

2.  Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm.

Authors:  Francis X McCormack; William D Travis; Thomas V Colby; Elizabeth P Henske; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2012-12-15       Impact factor: 21.405

3.  Gleason score 6 adenocarcinoma: should it be labeled as cancer?

Authors:  H Ballentine Carter; Alan W Partin; Patrick C Walsh; Bruce J Trock; Robert W Veltri; William G Nelson; Donald S Coffey; Eric A Singer; Jonathan I Epstein
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

4.  African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Authors:  Kosj Yamoah; Curtiland Deville; Neha Vapiwala; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Michael Kattan; Adam P Dicker; Timothy R Rebbeck
Journal:  Urol Oncol       Date:  2014-10-07       Impact factor: 3.498

5.  Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Authors:  Robert J Rounbehler; Anders E Berglund; Travis Gerke; Mandeep M Takhar; Shivanshu Awasthi; Weimin Li; Elai Davicioni; Nicholas G Erho; Ashley E Ross; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Robert B Jenkins; John L Cleveland; Jong Y Park; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-14       Impact factor: 4.254
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.